Louis Garguilo

ARTICLES BY LOUIS

  • 10/28/2021

    Remember when a lack of capacity was going to feel like a massive concrete slab blocking the road to a biopharmaceutical revolution? Instead, it's felt like so many bricks placed in the paths of individual drug development programs. Now CDMOs are building to meet demand. Is it the right kind of capacity?

  • 10/22/2021

    2.4 million sq ft of dormant industrial space undergoing adaptive reuse development as a biomanufacturing center in the heart of Philadelphia. Do we have your attention? Cell and gene therapy companies, CDMOs, Big Pharma: All are welcome to the renaissance.

  • 10/18/2021

    Today, cell-and-gene companies need knowledge support, and thus a “new sort of consultancy partnership focused on process development and advice-giving, not just routine CDMO contracts for services.” “CDMO 2.0” can materialize in an increasingly familiar form – drug-developer/service-provider hybrid organization.

  • 10/12/2021

    Massimo Dominici is on a mission to “GMP-ify” the cell-and-gene industry, and create a ubiquitous new “culture of cell culture,” as he puts it. To do that, the company he co-founded set out as an emerging, clinical-stage biopharma, and also became a service provider to other emerging CGT developers.

  • 10/7/2021

    Happy about it or otherwise, many readers will face a level of “site selection” – some of you coming face-to-face with economic development agencies at state, regional or local levels. What should you expect? We've got answers and advice.

  • 9/23/2021

    You are an emerging biopharma outsourcing to a trusted CDMO that has selected its location wisely – an important factor in your selecting it. Now you’ve determined to establish some of your own development or manufacturing facilities. Would it be beneficial to build close to your CDMO?

  • 9/16/2021

    With a more flexible and relational approach, CDMOs and emerging drug sponsors can end up putting together a different contract altogether – one driving a new pricing and calculation that works for both sides. Here's details to one example.

  • 9/13/2021

    Somebody has to set the strategic integration of in-house development and manufacturing with external activities; identify for investors why that is the wisest strategy; explain why the CDMO selected is the best fit. Those somebodies are CEOs. Here’s more from ISR Reports.

  • 9/8/2021

    What's really in it for your independent advisors and board members? We've some firsthand answers that will catalyze some thoughts on how you receive potentially invaluable advice from a trusted executive-level mentor, advisor, and additive governing voice – and not only regarding outsourcing.

  • 9/7/2021

    In the beginning, there were Big Pharma concentrations. Decades later, biotech centers emerged. Now we have our first CDMO cluster. It’s in North Carolina. And it’s worth giving this some thought if you are outsourcing drug development and manufacturing.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.